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Vascular access thrombosis is one of the major causes of morbidity in patients
maintained on chronic hemodialysis. Thrombophilia has been recognized as a risk
factor of vascular access thrombosis. The authors report a case of inherited protein S
deﬁciency associated with vascular access thrombotic events. DNA sequence analysis
of the PROS1 gene identiﬁed a novel heterozygous nonsense mutation in exon 10 by
transition of AAG (lysine) to TAG (stop codon) at codon 473 (c.1417A4T, p.K473X).
Results from the study suggest that the inherited protein S deﬁciency due to a PROS1
gene mutation may cause vascular access thrombosis in hemodialysis patients.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Vascular access thrombosis is relatively common in
patients on hemodialysis and becomes a major cause of
access failure. It is currently thought that most episodes of
ﬁstula thrombosis are consequences of underlying ana-
tomic abnormalities such as venous neointimal hyperplasia
or vascular stenosis formation [1]. However, various reports
have noted a signiﬁcant amount of spontaneous thrombosis
occurring independently of any obvious anatomic cause,
suggesting that an unexplained nonanatomic cause may be
responsible for a large number of thromboses. Thrombo-
philias are inherited or acquired predisposition of throm-
bosis and have been proposed as a possible cause of therean Society of Nephrology. P
ses/by-nc-nd/4.0/).
ternal Medicine, Seoul
umi-dong, Bundang-gu,hemodialysis access thrombosis [2]. A large case-controlled
study exhibited that the presence of thrombophilia
increased the risk for dialysis access thrombosis. Further-
more, it was shown that each additional thrombophilic
factor increased the likelihood of access thrombosis almost
twofold [3].
In recent years, several polymorphisms or point muta-
tions of proteins involved in the coagulation cascade have
been examined regarding their potential inﬂuence on
vascular access thrombosis [4]. However, little is known
about the roles of inherited protein S (PS) deﬁciency and
its genetic defect for vascular access thrombosis in main-
tenance hemodialysis. We present here a case of inherited
PS deﬁciency with recurrent vascular access thrombosis.Case report
A 58-year-old Korean man experienced more than three
episodes of thrombotic occlusions of hemodialysis vascularublished by Elsevier. This is an open access article under the CC BY-NC-
Figure 1. Axial and coronal images of CT angiography. CT angiogra-
phy shows a total occlusion of the right popliteal artery (arrow).
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1981, as chronic kidney disease associated with severe
vesicoureteral reﬂux. Kidney sonography showed bilateral
hydronephrosis, and the initial serum creatinine level was
3.5 mg/dL. Voiding cystourethrography revealed severe vesi-
coureteral reﬂux, and urethroscopy conﬁrmed congenital
posterior urethral valve. The patient underwent suprapubic
cystostomy, and after that, he had been hospitalized on
numerous occasions with cystostomy-related complications.
In September 1985, he progressed to end-stage renal disease
and started hemodialysis with an arteriovenous shunt in his
left wrist. In October 1988, he had an episode of arteriovenous
ﬁstula thrombosis, and a new Cimino shunt was placed in his
right wrist. Five years later, another shunt thrombosis
occurred, which was diagnosed by right upper extremity
arteriography, and it showed no anatomic abnormality. At
that time, another Cimino shunt was created in his left
forearm. During the evaluation of the patient’s second epi-
sode, his thrombophilic predisposition was disclosed. Less
than 20% of serum PS activity was determined by clotting
assays, whereas other coagulation studies were normal
(Table 1). He had started to receive antiplatelet agents after
this episode. However, another thrombotic event of vascular
access occurred in April 2000, and thrombectomy of the old
Cimino shunt was done. At that time, both upper angiogra-
phies were negative except for the presence of a thrombus at
the arteriovenous shunt. Electrocardiography (ECG) showed a
normal sinus rhythm. In August 2009, the patient presented
with painful swelling in his right leg, and through evaluation
with computed tomography, right popliteal artery thrombosis
was diagnosed (Fig. 1). The ECG revealed new-onset atrial
ﬁbrillation with slow ventricular response. Transesophageal
echocardiography was done to exclude the presence of atrial
thrombi, and although the ventricular systolic function and
cardiac valves were normal, an echogenic mobile mass at the
appendage of the left atrium was found. Based on the
transesophageal echocardiography ﬁndings and clinicalTable 1. Hemostatic Studies in the Patient
Events At ﬁrst event At second event
The year after AV ﬁstula
formation
3 year 5 year
Clinical feature Vascular access
thrombosis
Vascular access thrombos





Hemoglobin, g/dL 10.6 11
Hct, % 30.7 32
Platelets, /nL 179 199
PT, INR 1.01 1.02
aPTT 26 33.6
Fibrinogen, mg/dL 357 311
AT III, % 93
D-dimers 1.49
PS activity, % 13
PC activity, % 98
APL, IgG 2, negative
APL, IgM 1, negative
FANA Negative
APL, antiphospholipid; AT III, antithrombin III; FANA, ﬂuorescent ant
immunoglobulin M; INR, international normalized ratio; PS, protein S; PT,presentation, the mass was concluded to be a thrombus.
The patient underwent thrombectomy of the right popliteal
artery and was treated with heparin and subsequently with
oral anticoagulants under close supervision.
The family history revealed the thrombotic conditions
over three generations. The patient’s second eldest brother, a
66-year-old man, had spontaneous deep vein thrombosis of
the right leg at age 43 years, and thrombectomy of the right
femoral vein was done. His father, an 88-year-old man, had a
stroke at age 85 years. His paternal uncle and one cousin had
a history of strokes, and his paternal grandparents died from
stroke. The pedigree of the family is shown in Fig. 2.
Genetic analysis of the family was done to obtain a
molecular diagnosis, allowing screening for the family
members. A total of 28 members from 4 generations were
examined (Fig. 2). The PROS1 gene was screened by direct
DNA sequencing of polymerase chain reaction (PCR) pro-
ducts. After informed consent was obtained, the physician
extracted genomic DNA from the patient’s whole bloodAt third event At fourth event
Normal
values
7 year 9 year
is Vascular access
thrombosis

















inuclear antibody; Hct, hematocrit; IgG, immunoglobulin G; IgM,
prothrombin time.
Figure 2. Pedigree of the family under investigation. Squares and circles indicate males and females, respectively, and the squares and circles
that are crossed through indicate deceased family members. The arrow denotes the proposita. Black symbols indicate individuals who are affected
by PROS1 gene mutation (c.1417A4T, p.K473X), and gray symbols indicate those whose affection status is unknown.
Figure 3. DNA sequence analysis. DNA sequence analysis of PROS1 exon 10 for the patient reveals a novel nonsense mutation.
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intron boundary regions were ampliﬁed by PCR, and the PCR
products of 50 untranslational regions, coding regions of 15
exons, and ﬂanking regions of PROS1 gene were subjected to
direct sequencing using ABI PRISM 37301 DNA analyzer.
DNA sequencing revealed that the patient had a novel
heterozygous nonsense mutation. In exon 10 of the PROS1
gene, a transition AAG (lysine) to TAG (stop codon) at codon
473 by substitution of A to T at 1417 site (c.1417A4T,
p.K473X) was detected (Fig. 3). The same mutation was
found in three family members, including the patient’s
second eldest brother, father, and 28-year-old daughter,
who had no clinical history of thrombosis (Fig. 2).Discussion
Vascular access failure caused by thrombosis is a leading
cause of morbidity and hospitalization in the hemodialysis
population. Approximately 16–20% of all hospitalizations inthese patients are related to vascular access dysfunction
based on a survey done in the United States [5]. Inherited
PS deﬁciency is present in 2–5% of patients with thrombosis
and is considered a promoter of the hypercoagulable state
in such patients [6]. It is inherited as an autosomal
dominant trait, and heterozygous individuals frequently
have recurrent thromboembolism. Aortic and coronary
thrombosis, stroke, and renal vein thrombosis have also
been reported in PS-deﬁcient patients. In this case, we
showed PS deﬁciency could also be associated with
the thrombosis of vascular access. The patient suffered
multiple thrombotic occlusions of the arteriovenous shunt
without obvious anatomic cause. No other coagulation
abnormalities except PS deﬁciency were found, suggesting
that PS deﬁciency has a role in the thrombosis of vascular
access.
This case draws attention to PS deﬁciency in patients on
hemodialysis. There have been several studies investigating
the relationship of PS deﬁciency with vascular access
thrombosis, with a signiﬁcant correlation between them
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tests to conﬁrm PS deﬁciency, and the patient discussed
here represents a case of genetically conﬁrmed PS deﬁ-
ciency underlying the vascular access thrombosis.
PS deﬁciency is the most difﬁcult of all the hereditary
thrombophilias to document with certainty. Free PS is
probably the best screening test [9], although many use
the functional PS assay, which has a larger coefﬁcient of
variation. PS levels in plasma are subject to biologic,
physiologic, and pathologic inﬂuences [10]. Genetic ana-
lysis can be useful in the diagnosis [11].
PS is encoded by PROS1, which spans more than 80 kb of
genomic DNA, and is composed of 15 exons and 14 introns.
PROS1 is located near the centromere on chromosome
3q11.2 [6]. So far, almost 200 different PROS1 mutations
resulting in a loss of function have been identiﬁed [12].
Although many mutations in PROS1 have been reported, we
have identiﬁed another novel nonsense mutation. To our
knowledge, this is the ﬁrst description of a new mutation in
the PROS1 gene (c.1417A4T, p.K473X), which seems to have
clinical relevance with recurrent vascular access thrombosis.
The optimal management of patients with thrombophi-
lia-related vascular access thrombosis is still unclear. In
this case, the patient received antiplatelet agents after the
second thrombotic episode, and started anticoagulation
after a new-onset atrial ﬁbrillation was detected. An
antithrombin agent might increase vascular access graft
patency but is associated with the risk of serious hemor-
rhagic complications, especially in patients with end-stage
renal disease. Because of the important role of platelets in
thrombus formation, several antiplatelet agents such as
aspirin and clopidogrel have been used to prevent perio-
perative and long-term thrombosis [2].
In conclusion, this case illustrates that genetic anoma-
lies in the PS anticoagulation system could be an impor-
tant risk factor of vascular access thrombosis. The
inherited prothrombotic disorders might be considered
as the differential diagnosis of recurrent vascular access
thrombosis in patients with hemodialysis.Conﬂict of interest
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